The Israeli drug development co has raised $11 million on Nasdaq at a company valuation of $91 million.
Israeli drug development company Entera Bio has raised $11 million on Nasdaq at a company valuation of $91 million. This was the fourth attempt to list on Nasdaq by the Jerusalem based company which is developing treatments for osteoporosis and a rare thyroid condition.
Entera Bio offered 1.4 million shares at $8, the low end of the range of $8 to $10 and will list on Nasdaq with ENTX ticker. Maxim Group LLC acted as lead manager on the deal.
Published by Globes [online], Israel business news - www.globes-online.com - on July 1, 2018
© Copyright of Globes Publisher Itonut (1983) Ltd. 2018
drug development